December 3, 2009
Proteon Therapeutics Named 2010 Technology Pioneer by the World Economic Forum.
Award Recognizes Innovative Start-ups Poised to Impact the Future of Business and Society
Download article (pdf)
November 23, 2009
Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients.
Proteon Also Announces Gregory D. Phelps Appointed as Chairman of the Board.
Download article (pdf)
June 8, 2009
Proteon Founders Nicholas Franano, M.D. and William P. Whitaker, Esq. Named Ernst &
Young Entrepreneur Of The Year® 2009 Award Winners in the Central Midwest Region.
Award Recognizes Entrepreneurial Excellence in Private Equity/Venture Capital Backed Category.
Download article (pdf)
May 28, 2009
Proteon Therapeutics Completes Second Closing of Equity Financing;
Raises Total Series B to $50 million.
Proteon also receives orphan drug designation for its lead product candidate, PRT-201
Download article (pdf)
March 5, 2009
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement with Major Pharmaceutical Company
Download article (pdf)
November 5, 2008
Proteon Therapeutics Presents New Data on PRT-201 at the Annual Meeting of the American Society of Nephrology in Philadelphia.
Download article (pdf)
October 13, 2008
Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008.
Download article (pdf)
September 9, 2008
Proteon Therapeutics, Inc., announced today it has received Food and Drug Administration (FDA) fast track designation for the development program for PRT-201.
Download article (pdf)
March 12 , 2008
Proteon Therapeutics appoints Gregory D. Phelps, a seasoned biopharmaceutical executive, to the Company's Board of Directors.
Download article (pdf)
March 12, 2008
Proteon Therapeutics, Inc., announced today that a key patent has been issued by the European Patent Office.
Download article (pdf)
November 1, 2007
Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
Download article (pdf)
September 6, 2007
Proteon Therapeutics completes $12 million financing and hires CFO
Download article (pdf)
January 23, 2007
Proteon Therapeutics receives second issued U.S. patent broadly covering elastase vasodilation
Download article (pdf)
September 12, 2006
Proteon Therapeutics adds experienced research and drug development talent to its team
Download article (pdf)
August 28, 2006
EDC of Kansas City announces creation of “Kansas City Biotechnology Center”
Download article (pdf)
June 26, 2006
Proteon Therapeutics receives issued U.S. patent broadly covering new method of artery and vein dilation
Download article (pdf)
June 21, 2006
Proteon Therapeutics selects QSV Biologicals, Ltd for PRT-201 manufacturing
Download article (pdf)
May 10, 2006
Proteon Therapeutics hires veteran biotechnology executive Timothy Noyes as CEO
Download article (pdf)
March 29, 2006
Proteon Therapeutics, Inc. closes $19M in Series A financing
Download article (pdf)
January 13, 2006
Proteon Therapeutics, LLC and The University of Kansas Medical Center present at the annual meeting of the American Society of Nephrology
Download article (pdf)
January 13, 2006
Proteon Therapeutics, LLC closes $927,000 round of angel financing
Download article (pdf)
January 12, 2005
Proteon Therapeutics, LLC awarded grant by National Institutes of Health for new cardiovascular drug development program
Download article (pdf)
July 23, 2004
Proteon Therapeutics, LLC announces award of STTR grant
Download article (pdf)
June 22, 2004
Proteon Therapeutics, LLC research labs to locate in the Biotechnology Development Center of Greater Kansas City
Download article (pdf)
Headlines
Proteon Therapeutics completes $12 million financing and hires CFO.
Proteon Therapeutics receives second issued U.S. patent broadly covering elastase vasodilation.
Proteon Therapeutics adds experienced research and drug development talent to its team.
EDC of Kansas City announces creation of “Kansas City Biotechnology Center”.
Proteon Therapeutics selects QSV Biologicals, Ltd for PRT-201 manufacturing.
Proteon Therapeutics hires veteran biotechnology executive as CEO.
Proteon Therapeutics, Inc. closes $19M in Series A financing.
